-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Major Shareholder Holding Ltd Roche Sells 75,000 Shares
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Major Shareholder Holding Ltd Roche Sells 75,000 Shares
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) major shareholder Holding Ltd Roche sold 75,000 shares of Jasper Therapeutics stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $1.89, for a total transaction of $141,750.00. Following the completion of the transaction, the insider now directly owns 4,549,606 shares of the company's stock, valued at approximately $8,598,755.34. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Jasper Therapeutics Stock Down 2.7 %
JSPR stock traded down $0.05 during midday trading on Thursday, reaching $1.80. The company had a trading volume of 742,983 shares, compared to its average volume of 11,078,075. Jasper Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $5.81. The stock has a 50 day moving average price of $1.00 and a 200-day moving average price of $1.28.
Get Jasper Therapeutics alerts:Jasper Therapeutics (NASDAQ:JSPR – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms have commented on JSPR. Oppenheimer decreased their price objective on shares of Jasper Therapeutics from $21.00 to $8.00 and set an "outperform" rating on the stock in a report on Monday, November 14th. Credit Suisse Group decreased their price target on shares of Jasper Therapeutics from $7.00 to $3.00 and set an "outperform" rating on the stock in a research note on Wednesday, January 11th. Finally, EF Hutton Acquisition Co. I restated a "buy" rating and set a $4.00 price objective on shares of Jasper Therapeutics in a report on Wednesday, January 11th.Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC increased its holdings in Jasper Therapeutics by 3.8% in the 3rd quarter. Citadel Advisors LLC now owns 3,102,016 shares of the company's stock worth $2,448,000 after purchasing an additional 112,913 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Jasper Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 530,120 shares of the company's stock valued at $418,000 after buying an additional 49,559 shares during the period. UBS Group AG boosted its position in Jasper Therapeutics by 3,294.6% during the 3rd quarter. UBS Group AG now owns 188,026 shares of the company's stock worth $148,000 after buying an additional 182,487 shares during the period. State Street Corp bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $77,000. Finally, Renaissance Technologies LLC bought a new position in shares of Jasper Therapeutics during the first quarter valued at $39,000. 68.37% of the stock is currently owned by institutional investors and hedge funds.
Jasper Therapeutics Company Profile
(Get Rating)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
Featured Stories
- Get a free copy of the StockNews.com research report on Jasper Therapeutics (JSPR)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) major shareholder Holding Ltd Roche sold 75,000 shares of Jasper Therapeutics stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $1.89, for a total transaction of $141,750.00. Following the completion of the transaction, the insider now directly owns 4,549,606 shares of the company's stock, valued at approximately $8,598,755.34. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Jasper Therapeutics, Inc.(纳斯达克股票代码:JSPR — 获取评级)主要股东控股有限公司罗氏在1月25日星期三的一笔交易中出售了7.5万股Jasper Therapeutics股票。这些股票的平均价格为1.89美元,总交易额为141,750.00美元。交易完成后,知情人现在直接拥有该公司4,549,606股股票,价值约为8,598,755.34美元。此次出售是在向美国证券交易委员会提交的文件中披露的,该文件可通过以下方式获得 美国证券交易委员会网站。拥有公司10%以上股票的主要股东必须披露他们与美国证券交易委员会的交易。
Jasper Therapeutics Stock Down 2.7 %
贾斯珀疗法股价下跌2.7%
JSPR stock traded down $0.05 during midday trading on Thursday, reaching $1.80. The company had a trading volume of 742,983 shares, compared to its average volume of 11,078,075. Jasper Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $5.81. The stock has a 50 day moving average price of $1.00 and a 200-day moving average price of $1.28.
周四午盘交易中,JSPR股票下跌0.05美元,至1.80美元。该公司的交易量为742,983股,而平均交易量为11,078,075股。Jasper Therapeutics, Inc.创下1年低点0.39美元,1年高点为5.81美元。该股的50天移动平均价格为1.00美元,200天移动平均线价格为1.28美元。
Jasper Therapeutics (NASDAQ:JSPR – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.
Jasper Therapeutics(纳斯达克股票代码:JSPR — 获取评级)最后一次发布财报是在11月10日星期四。该公司公布了本季度每股收益(0.32美元),比市场普遍预期的(0.35美元)高出0.03美元。卖方分析师预计,Jasper Therapeutics, Inc.将在本财年公布每股收益为-1.34美元。
Analysts Set New Price Targets
分析师设定了新的价格目标
Institutional Inflows and Outflows
机构流入和流出
Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC increased its holdings in Jasper Therapeutics by 3.8% in the 3rd quarter. Citadel Advisors LLC now owns 3,102,016 shares of the company's stock worth $2,448,000 after purchasing an additional 112,913 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Jasper Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 530,120 shares of the company's stock valued at $418,000 after buying an additional 49,559 shares during the period. UBS Group AG boosted its position in Jasper Therapeutics by 3,294.6% during the 3rd quarter. UBS Group AG now owns 188,026 shares of the company's stock worth $148,000 after buying an additional 182,487 shares during the period. State Street Corp bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $77,000. Finally, Renaissance Technologies LLC bought a new position in shares of Jasper Therapeutics during the first quarter valued at $39,000. 68.37% of the stock is currently owned by institutional investors and hedge funds.
一些机构投资者最近修改了他们持有的该股。Citadel Advisors LLC在第三季度将其在Jasper Therapeutics的持股量增加了3.8%。Citadel Advisors LLC在上个季度又购买了112,913股股票后,现在拥有该公司3,102,016股股票,价值244.8万美元。Vanguard Group Inc.在第三季度将其在Jasper Therapeutics的股份增加了10.3%。Vanguard Group Inc.在此期间又购买了49,559股股票后,现在拥有该公司530,120股股票,价值41.8万美元。瑞银集团股份公司在第三季度将其在Jasper Therapeutics的头寸提高了3,294.6%。瑞银集团股份公司在此期间又购买了182,487股股票后,现在拥有该公司188,026股股票,价值14.8万美元。State Street Corp在第一季度收购了Jasper Therapeutics的新股份,价值约77,000美元。最后,Renaissance Technologies LLC在第一季度购买了Jasper Therapeutics股票的新头寸,价值39,000美元。该股票的68.37%目前由机构投资者和对冲基金持有。
Jasper Therapeutics Company Profile
贾斯珀疗法公司简介
(Get Rating)
(获取评分)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
Jasper Therapeutics, Inc是一家临床阶段的生物技术公司,开发用于造血干细胞移植和基因疗法的治疗药物。它侧重于调理药物和干细胞工程的开发和商业化,以扩大干细胞移植和体外基因疗法的使用,即在移植之前在体外对细胞进行基因操纵。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Jasper Therapeutics (JSPR)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
- 免费获取 StockNews.com 关于 Jasper Therapeutics (JSPR) 的研究报告
- 雪佛龙通过750亿美元的股票回购使股东感到高兴
- 电子商务的未来:分析和新数据
- 李维·施特劳斯非常适合收入投资者
- 3 个有很大上升空间的小盘股
- Mullen Automotive:好消息、坏消息和丑陋前景
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《贾斯珀疗法日报》的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Jasper Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧